Design and Synthesis of Pyridone-Containing 3,4-Dihydroisoquinoline-1(2 <i>H</i> )-ones as a Novel Class of Enhancer of Zeste Homolog 2 (EZH2) Inhibitors

Pei‐Pei Kung(Pfizer (United States)), Martin P. Edwards(Pfizer (United States)), Luke R. Zehnder(University of Minnesota), Martha A. Ornelas(Pfizer (United States)), Sacha Ninkovic(Pfizer (United States)), Michael Ryskin(Pfizer (United States)), John Braganza(Pfizer (United States)), Michael R. Collins(Pfizer (United States)), Patrick Bingham(Pfizer (United States)), Simon Bergqvist(Pfizer (United States)), Shinji Yamazaki, Susan E. Kephart(Pfizer (United States)), Robert A. Kumpf(Pfizer (United States)), Peter A. Wells(Pfizer (United States)), Valeria R. Fantin(AVEO Oncology (United States)), Martin Wythes(Pfizer (United States)), Indrawan McAlpine(Pfizer (United States)), Hovhannes J. Gukasyan(Pfizer (United States)), Karen A. Maegley(Pfizer (United States)), Mei Cui(Tianjin University), Wenyue Hu(Beijing University of Chinese Medicine), Eugene Rui(Unknown), Dominique Verhelle(Pfizer (United States)), Brian Yip(Pfizer (United States)), Wade Diehl(Pfizer (United States)), Cody Krivacic(Pfizer (United States)), Gang Li(Pfizer (United States)), Fen Wang(Texas A&M Health Science Center), Scott C. Sutton(Pfizer (United States)), Xiu Yu(Pfizer (United States)), Dac M. Dinh(Pfizer (United States)), Weiguo Zhang(Universidade Estadual de Londrina), Stephanie Scales(Pfizer (United States)), John Tatlock(Pfizer (United States)), Robert A. Rollins(Pfizer (United States)), Connie Fan(Pfizer (United States)), Buwen Huang(Pfizer (United States)), Lisa Nguyen(Pfizer (United States))
Journal of Medicinal Chemistry
August 11, 2016
10.1021/acs.jmedchem.6b00515
Cited by 69

Related Papers

Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance
|Cancer Cell|2006|1.6k
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal–Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
|Journal of Medicinal Chemistry|2011|924
Discovery of (10 <i>R</i> )-7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro- <i>2H</i> -8,4-(metheno)pyrazolo[4,3- <i>h</i> ][2,5,11]-benzoxadiazacyclotetradecine-3-carbonitrile (PF-06463922), a Macrocyclic Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-ros Oncogene 1 (ROS1) with Preclinical Brain Exposure and Broad-Spectrum Potency against ALK-Resistant Mutations
|Journal of Medicinal Chemistry|2014|587
Using the Golden Triangle to optimize clearance and oral absorption
|Bioorganic & Medicinal Chemistry Letters|2009|382